New tip sheet available for the Behavioral Health HEDIS measure: Follow-Up Care for Children Prescribed ADHD Medication (ADD)

Nov. 2022Important Notices
The ADD HEDIS® measure outlines the importance for members 6 to 12 years old who are newly prescribed a medication for ADHD to receive, at minimum, three appointments—an initial appointment with the prescriber and subsequent appointments with the treatment team, including behavioral health treatment providers—within 10 months of starting the new medication. The tip sheet defines the HEDIS measure and offers providers tips to ensure continuity of care for their patients who are prescribed medications for ADHD for the first time. Learn more about the ADD HEDIS measure.

HEDIS®
The Healthcare Effectiveness Data and Information Set (HEDIS®) is a registered trademark of NCQA.

Recent Announcements

CME Webinar: Lifestyle Medicine in Practice: Evidence‑Based Strategies for Chronic Disease Care

Please join us for a live, CME-accredited webinar on Wednesday, Sept. 23 from noon to 1 p.m., that will provide an overview on lifestyle medicine. Participants will learn how to integrate six core domains—nutrition, physical activity, sleep, stress management, avoidance of risky substances, and social connection—into routine care using practical tools such as brief counseling, motivational interviewing, and team-based strategies.
Sep. 2026Education/Webinars

Voluntary nationwide recall: Thyroid (Vitruvias – August 2026)

Vitruvias Therapeutics Inc. is recalling one lot, lot 504950, of Thyroid Tablets, USP 30 mg. Thyroid Tablet is used to treat hypothyroidism (underactive thyroid).
Sep. 2026Pharmacy Updates

Voluntary nationwide recall: Dextrose (Baxter – August 2026)

Baxter International Inc. is recalling one lot (lot Y495066) of 70% Dextrose Injection. Dextrose is used to replenish calories and fluid in certain situations.
Sep. 2026Pharmacy Updates